ClinicalTrials.gg
RecruitingNCT06171607Updated Feb 2, 2026

Contrast Enhanced Ultrasound Medical Imaging for Identifying Breast Masses

A Phase 1 interventional study of Contrast-Enhanced Ultrasound and Perflutren Lipid Microspheres in Breast Carcinoma, sponsored by University of Southern California. Recruiting at 2 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-02.

Sponsored by University of Southern California · Phase 1, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Registered 1 year 8 months after the study started (first participant enrolled Nov 2020, registered Jul 2022).
  • Started Nov 2020; still recruiting 6 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 10 studies testing perflutren in Breast Neoplasms — 3 open to participants now, 4 under way, 1 of them phase 3. perflutren · Breast Neoplasms.

Planned enrollment
4th of 10
100 · median 32
Started
2020
with 2 others
Phase 1
5 of 10
2 open now
Registered
8th of 10
by date
Lead sponsor
2 of 10
University of Southern California

Among the 10 studies testing perflutren in Breast Neoplasms, this one is the 4th largest by planned enrollment, is one of 3 that started in 2020, is one of 5 in phase 1, and was the 8th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

3 of the 10 studies testing perflutren in Breast Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

About perflutren

perflutren: first FDA approval 2001 (DEFINITY), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing perflutren in Breast Neoplasms, or all of them as a file.
02

Study summary

This clinical trial investigates the role of contrast enhanced ultrasound (CEUS) in identifying cystic breast masses as benign or malignant. Ultrasound is a diagnostic imaging test that uses sound waves to make pictures of the body without using radiation (x-rays). Ultrasounds are widely used to diagnose many diseases in the body. This trial may help researchers learn if using CEUS will help in determining whether or not an ultrasound guided biopsy is necessary.

Read the detailed description

PRIMARY OBJECTIVES:

I. To examine and compare the distribution of CEUS parameters in breast masses that were evaluated as Breast Imaging Reporting and Data System (BI-RADS) 4a, 4b, 4c or 5 by conventional ultrasound (US) and were recommended for ultrasound guided biopsy, and to evaluate whether these parameters can be used to classify suspicious cystic-appearing breast masses as benign or malignant.

Ia. To develop a CEUS-based radiomics workflow to extract radiomic metrics (> 1600 features) in classifying breast mass malignancy (Radiomics).

Ib. To develop a systematic and rigorous machine learning (ML)-based framework comprised of classification, cross-validation and statistical analyses to identify the best performing classifier for breast malignancy stratification based on CEUS-derived radiomic metrics (time-intensity curve [TIC] analysis and Radiomics).

Ic. To assess the independent contribution of radiomics classifier and time-intensity curve classifier to the model accuracy in discriminating benign from malignant cases (TIC analysis versus [vs.] Radiomics).

Id. To assess the potential benefit of machine learning classifier in preventing unnecessary biopsy (TIC analysis and Radiomics).

OUTLINE:

Patients receive a contrast agent (Lumason or DEFINITY) intravenously (IV) and then undergo CEUS scan over 60-90 minutes.

03

Conditions studied

  • Breast Carcinoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Newly diagnosed breast masses assigned as BIRADS 4a, 4b, 4c or 5 by conventional US and recommended for ultrasound guided
  • Age >= 18 years
  • Female

Exclusion criteria

Exclusion Criteria:

  • to microbubble contrast: Patients who have a known pulmonary hypertension and any known to US contrast agent
  • Women with renal failure or insufficiency (only if patient is receiving CESM scan)
  • Women with Iodine contrast allergy (only if patient is receiving CESM scan)
  • Women with the largest side of the mass measuring ≤ 1 cm (only if patient is receiving CEUS scan)
  • Women who are pregnant, possibly pregnant, or lactating
  • Women currently undergoing chemotherapy
  • Women \< 18 years of age
  • Patient ≤ 30 years (only if patient is receiving CESM scan)
  • Masses in the same breast that had prior lumpectomy for cancer
  • Women with cancer in the same breast will be excluded however, women with cancer in the contralateral breast will be eligible to participate in the study
  • Women with an allergy to perflutren (only if patient is receiving CEUS scan)
  • Prior history of for that specific lesion
  • Women with breast implants
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Phase 1
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Diagnostic (contrast agent, CEUS)

    Patients receive a contrast tracer (Lumason or DEFINITY) IV and then undergo CEUS scan over 60-90 minutes.

    Procedure: Contrast-Enhanced Ultrasound · Drug: Perflutren Lipid Microspheres · Drug: Sulfur Hexafluoride Lipid Microspheres

Interventions

06

What researchers measure

Primary outcomes

  1. Radiomics-based ML-classifier framework

    The performance of radiomics-based ML classifier framework will be compared to the performance of the TIC metrics. The joint performance of radiomics and TIC analysis will be compared to their individual performances. The classifier performance will be assessed using the area under curve (AUC). The Z-test will be used to compare the difference between the area under the curves 1) AUCboth versus (vs.) AUCradiomic 2) AUCboth vs. AUCTIC 3) AUCTIC vs. AUCradiomic.

    Time frame: Up to 12 months

  2. Performance of radiomics-based ML approach to prevent unnecessary biopsies

    Will assess the percentage of benign cases that can be classified as benign by ML (Specificity) thus been prevented from biopsy. Will select the diagnostic cut-off point based on the ROC curve constructed from the predicted probability. Such a cut-off point will result in a maximal sensitivity (100%). Specificity with 95% Clopper Pearson confidence interval will be obtained.

    Time frame: Up to 12 months

07

Study locations

2 of 2 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2020 (actual). Primary completion is estimated for Nov 2026, 72 months after the start.

Of 373 non-industry phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 77. This study's planned 72 months is above that.

Counting every sponsor, half of 763 studies reached it within 44 months; a quarter within 25 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2022
First posted
Dec 14, 2023
StartActual
Nov 5, 2020
Primary completionEst.
Nov 5, 2026
CompletionEst.
Nov 5, 2027
Last update
Feb 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06171607
Responsible party
Sponsor
First posted
Dec 14, 2023
Start date
Nov 5, 2020
Primary completion
Nov 5, 2026 (estimated)
Completion
Nov 5, 2027 (estimated)
Last update
Feb 2, 2026

Study contacts

Janet Jaime
Contact
Janet.jaime@med.usc.edu
323-865-3205
Bino A Varghese, PhD
principal investigator · University of Southern California

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Perflutren · Sulfur Hexafluoride

Start the discussion